Ptc Therapeutics (PTCT) Asset Writedowns and Impairment (2023 - 2025)

Ptc Therapeutics' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $500000.0 for Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment fell 99.68% year-over-year to $500000.0; the TTM figure through Dec 2025 stood at $159.1 million (changed 0.31% YoY), while the FY2025 annual figure was $1.0 million, down 99.36% from the prior year.
• Asset Writedowns and Impairment for Q4 2025 stood at $500000.0, up from $400000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $217.8 million in Q2 2023, with the low at $100000.0 in Q2 2025.
• The 3-year median for Asset Writedowns and Impairment is $500000.0 (2025), against an average of $54.1 million.
• The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment plunged 99.91% in 2024, then plunged 50.0% in 2025.
• Ptc Therapeutics' Asset Writedowns and Impairment stood at $217.8 million in 2023, then fell by 27.43% to $158.1 million in 2024, then tumbled by 99.68% to $500000.0 in 2025.
• Business Quant data shows PTCT's Asset Writedowns and Impairment at $500000.0 in Q4 2025, $400000.0 in Q3 2025, and $100000.0 in Q2 2025.